MedTrace Logo

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

NCT06085742 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-19

No results posted yet for this study

Summary

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.

Conditions

Interventions

DRUG

Capecitabine

825mg/m2 PO BID on days 1-14

DRUG

Cyclophosphamide

60mg/m2 PO once a day (21 continuous days)

DRUG

Methotrexate

10mg/m2 PO BID on days 1, 8, and 15

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-22
Primary Completion
2034-09-30
Completion
2034-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06085742 on ClinicalTrials.gov